OCTREOTIDE ACETATO ( DrugBank: Octreotide )


1 disease
IDDisease name (Link within this page)Number of trials
227Osler disease1

227. Osler disease


Clinical trials : 54 Drugs : 73 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-004179-11-IT
(EUCTR)
03/09/202117/08/2021Effectiveness of somatostatin analogues for GI bleeding in patients with hereditaryhemorrhagic telangiectasiaEffectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagictelangiectasia and symptomatic gastrointestinal bleeding, SAIPAN-trial: a multicentre,randomized, open-label, parallel-group, superiority trial. - SAIPAN study Hereditary hemorrhagic telangiectasia (HHT), also known as Osler–Weber–Rendu disease(in specific patients with gastrointestinal bleeding and transfusion dependency)
MedDRA version: 21.0;Level: PT;Classification code 10019883;Term: Hereditary haemorrhagic telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: octreotide a azione pronta 0,1 mg
Product Code: [OCTREOTIDE ACETATO]
INN or Proposed INN: OCTREOTIDE ACETATO
RADBOUD UNIVERSITY MEDICAL CENTERNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
38Phase 3France;Denmark;Netherlands;Germany;United Kingdom;Italy